JP2021529807A - タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 - Google Patents

タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 Download PDF

Info

Publication number
JP2021529807A
JP2021529807A JP2021500187A JP2021500187A JP2021529807A JP 2021529807 A JP2021529807 A JP 2021529807A JP 2021500187 A JP2021500187 A JP 2021500187A JP 2021500187 A JP2021500187 A JP 2021500187A JP 2021529807 A JP2021529807 A JP 2021529807A
Authority
JP
Japan
Prior art keywords
substituted
optionally substituted
optionally
alkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529807A5 (https=
Inventor
ジン，ジェン
アイリー，ハンナ
リウ，ジン
ション，ヤン
バイアリー，ジェシカ
トミタ，シャノン
フー，ジェンピン
Original Assignee
アイカーン スクール オブ メディスン アット マウント シナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディスン アット マウント シナイ filed Critical アイカーン スクール オブ メディスン アット マウント シナイ
Publication of JP2021529807A publication Critical patent/JP2021529807A/ja
Publication of JP2021529807A5 publication Critical patent/JP2021529807A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021500187A 2018-07-05 2019-07-03 タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 Pending JP2021529807A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694118P 2018-07-05 2018-07-05
US62/694,118 2018-07-05
PCT/US2019/040507 WO2020010204A1 (en) 2018-07-05 2019-07-03 Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2021529807A true JP2021529807A (ja) 2021-11-04
JP2021529807A5 JP2021529807A5 (https=) 2022-07-11

Family

ID=69060000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500187A Pending JP2021529807A (ja) 2018-07-05 2019-07-03 タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法

Country Status (6)

Country Link
US (1) US20230070613A1 (https=)
EP (1) EP3817745A4 (https=)
JP (1) JP2021529807A (https=)
CN (1) CN112714646A (https=)
CA (1) CA3105121A1 (https=)
WO (1) WO2020010204A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN113354619B (zh) * 2021-06-24 2024-03-19 皖南医学院 一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用
CN113956233B (zh) * 2021-10-22 2023-06-06 南方医科大学 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
CA3242835A1 (en) * 2022-01-07 2023-07-13 Dana-Farber Cancer Institute, Inc. Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
WO2016168992A1 (en) * 2015-04-21 2016-10-27 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
WO2016197032A1 (en) * 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
JP2016540811A (ja) * 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
WO2016208595A1 (ja) * 2015-06-22 2016-12-29 小野薬品工業株式会社 Ｂｒｋ阻害化合物
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024319A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017079267A1 (en) * 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
JP2017513862A (ja) * 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101316101B1 (ko) * 2011-05-26 2013-10-11 연세대학교 산학협력단 Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
GB201516243D0 (en) * 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
ES2909234T3 (es) * 2016-12-21 2022-05-05 Ono Pharmaceutical Co Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
JP2016540811A (ja) * 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
JP2017513862A (ja) * 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2016168992A1 (en) * 2015-04-21 2016-10-27 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
WO2016197032A1 (en) * 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016208595A1 (ja) * 2015-06-22 2016-12-29 小野薬品工業株式会社 Ｂｒｋ阻害化合物
WO2017024319A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017079267A1 (en) * 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARDENAS, MARIEL M. ET AL.: "Enantioselective Synthesis of Pyrrolopyrimidine Scaffolds through Cation-Directed Nucleophilic Aroma", ORGANIC LETTERS, vol. 20, no. 7, JPN6023027300, 2018, pages 2037 - 2041, ISSN: 0005259654 *
MAHMOUD, K. A. ET AL.: "Discovery of 4-anilino α-carbolines as novel Brk inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 8, JPN6023027304, 2014, pages 1948 - 1951, ISSN: 0005259655 *
ZENG, H. ET AL.: "Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, no. 19, JPN6023027299, 2011, pages 5870 - 5875, ISSN: 0005259653 *

Also Published As

Publication number Publication date
WO2020010204A1 (en) 2020-01-09
CN112714646A (zh) 2021-04-27
US20230070613A1 (en) 2023-03-09
EP3817745A4 (en) 2022-04-06
EP3817745A1 (en) 2021-05-12
CA3105121A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
JP2021529807A (ja) タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法
JP7503851B2 (ja) Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
JP7829523B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
JP2021527666A (ja) Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
KR102506324B1 (ko) 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물
JP2022174114A (ja) Ａｌｋタンパク質分解剤及びそれらの癌療法における使用
EP3762381B1 (en) Bivalent agents comprising a serine threonine kinase (akt) ligand covalently linked to a degradation/disruption moiety for the treatment of cancer
EP4736882A2 (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
JP2020514252A (ja) Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
CA3091041A1 (en) Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
KR20190015250A (ko) 아르기나제 저해제 및 이의 치료적 용도
CA2922532A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
EP2681190A1 (en) Pyrrolidine derivatives as selective glycosidase inhibitors and uses thereof
US20230391765A1 (en) Heterobifunctional compounds as degraders of enl
US8476290B2 (en) Compound having spiro-bonded cyclic group and use thereof
CA3238094A1 (en) Lpa receptor antagonists and uses thereof
JP7783174B2 (ja) 四員環誘導体の調節剤、調製方法及びその利用
US20250136589A1 (en) Heterobifunctional compounds as hpk1 degraders
CN114269747A (zh) 一种1’,2’-二氢-3’h-螺[环丁烷1,4’-异喹啉]-3’-酮衍生物及其应用
CN102066345B (zh) *唑烷衍生物作为nmda拮抗剂
JP2023526840A (ja) ピペラジン複素環アミド尿素類を含む受容体共役タンパク質１阻害剤
WO2019241663A1 (en) Ccl5 inhibitors
CN112218878A (zh) Ntcp抑制剂
US20260055057A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
HK40070738B (en) Heterobifunctional compounds as degraders of hpk1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213